A Phase 3 interventional study of Pegcetacoplan and Placebo matching Pegcetacoplan in Cold Agglutinin Disease, sponsored by Swedish Orphan Biovitrum. Completed at 44 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-30.
Sponsored by Swedish Orphan Biovitrum · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Anemia, Hemolytic, Autoimmune with a site in Spain — 2 open to participants now, 7 under way, 5 of them phase 3. Anemia, Hemolytic, Autoimmune · Spain.
Among the 15 studies in Anemia, Hemolytic, Autoimmune with a site in Spain, this one is the 9th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2022, is one of 9 in phase 3, and was the 10th registered.
103 studies on the registry are indexed under Anemia, Hemolytic, Autoimmune; 39 are open to participants now.
Browse Anemia, Hemolytic, Autoimmune studies →2 of the 15 studies in Anemia, Hemolytic, Autoimmune with a site in Spain are open now. Recruiting first, the newest first:
Sanofi · Sites in Spain, United States, Argentina and 15 more countries
Ages 18+
Rigel Pharmaceuticals · Sites in Spain, United States, Australia and 15 more countries
Ages 18–100
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 24 Anemia, Hemolytic, Autoimmune studies recruiting now, 12 (50%) set no upper age limit and 10 (42%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 10
First in 2018; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is close to the median of 23 across 78 interventional studies indexed under Anemia, Hemolytic, Autoimmune.
Median enrollment 36 across the 14 interventional studies, 429 across the 1 observational. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 15 have an industry lead sponsor. The 10 most frequent:
Swedish Orphan Biovitrum is the lead sponsor of 82 studies on the registry; 6 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
Swedish Orphan Biovitrum has 1 study filed under Anemia, Hemolytic, Autoimmune — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Anemia, Hemolytic, Autoimmune with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to determine the efficacy of pegcetacoplan administration compared to placebo in increasing hemoglobin (Hgb) level from baseline and avoiding transfusion in participants with primary cold agglutinin disease (CAD).
This is a blind (actual treatment not disclosed to Investigator or participant) study to study pegcetacoplan in people with cold agglutinin disease. The study will consist of a 4-week screening period where selected tests will be conducted to ensure that the patient is eligible to participate in the study, followed by Part A, a 24-week blinded treatment period where the participants will receive either pegcetacoplan or a placebo treatment, looking like pegcetacoplan but with no effect. After this period, the participants will move into Part B, a 24-week period where they will all receive pegcetacoplan. Part C is a 48-week maintenance period with pegcetacoplan for all participants. After the end of treatment participants will undergo a safety follow visit about 8 weeks after last dose.
All eligible study participants will receive pegcetacoplan or placebo treatment, administered via subcutaneous infusion twice a week at home. The subcutaneous infusion requires two small needles to be inserted into the fatty layer of tissue under the skin and the investigational medication will flow into the body. Study participants and/or caregivers will be trained on home administration of pegcetacoplan.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Men must agree to the following for the duration of the study and 8 weeks after their last IMP dose:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1080 mg, subcutaneous injection, twice weekly
Drug: Pegcetacoplan
Sodium acetate, subcutaneous injection, twice weekly
Drug: Placebo matching Pegcetacoplan
1080 mg, subcutaneous injection, twice weekly
Drug: Pegcetacoplan
Sodium acetate, subcutaneous injection, twice weekly
Drug: Placebo matching Pegcetacoplan
Pegcetacoplan taken twice weekly as subcutaneous injection
Also known as: Aspaveli, Empaveli
Placebo matching pegcetacoplan taken twice weekly as subcutaneous injection
Number of Patients Achieving a Response (R) at Week 24
A participant was considered to have a response if the Hgb level increased greater than or equal to (\>=) 1.5 gram per deciliter (g/dL) from baseline and this increase was maintained from Week 16 through Week 24 in absence of blood transfusion from Week 5 through Week 24.
Time frame: Week 24
Change From Baseline to Week 24 in Hemoglobin (Hgb) Level-Part A in the Absence of Intercurrent Events (ICEs).
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange) Mean change from Baseline to Week 24 in Hemoglobin (Hgb) level.
Time frame: Week 24
Number of Patients Achieving Transfusion Avoidance From Week 5 to Week 24-Part A
Percentage of patients who did not receive a blood transfusion between Week 5 and Week 24 was assessed
Time frame: Week 24
Change From Baseline to Week 24 in FACT-An Scale Score (Quality of Life)-Part A in the Absence of Intercurrent Events (ICEs)
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). FACT-An is used to measure quality of life (QoL) in patients with anemia. Each item is rated on a 5-point Likert scale:0=Not at all, 1=A little bit ,2=Somewhat, 3=Quite a bit, 4=Very much. Some items are reverse scored. Higher scores in this scale denote a better QoL with less impact of anemia.The total FACT-An scale score ranges from 0 to 160. The total score gives a comprehensive view of a patient's well-being. It combines the FACT-G with an Anemia subscale. FACT-G (27 items):Physical Well-Being (PWB) and Social/Family Well-Being (SWB) 14 items in total, Emotional Well-Being (EWB)-6 items,Functional Well-Being (FWB)-7 items, Anemia Subscale (AnS): 13 items. Total FACT-An score=FACT-G + Anemia Subscale=40 item
Time frame: Week 24
Number of Packed Red Blood Cell Transfusions Received by Patients From Week 5 to Week 24-Part A
Number of blood transfusions received between Week 5 and Week 24 were assessed.
Time frame: Week 24
Change From Baseline to Week 24 in LDH Levels-Part A in the Absence of Intercurrent Events (ICEs)
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange) Mean change from baseline to Week 24 in Lactate dehydrogenase (LDH) levels
Time frame: Week 24
Change From Baseline to Week 24 in Haptoglobin Levels-Part A in the Absence of Intercurrent Events (ICEs)
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from baseline to Week 24 in Haptoglobin level
Time frame: Week 24
Change From Baseline to Week 24 in Indirect Bilirubin-Part A in the Absence of Intercurrent Events (ICE)
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from baseline to Week 24 in Indirect bilirubin level
Time frame: Week 24
Change From Baseline to Week 24 in ARC-Part A in the Absence of Intercurrent Events (ICEs)
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from baseline to Week 24 in Absolute reticulocyte counts (ARC).
Time frame: Week 24
Change From Baseline to Week 24 in D-dimer Levels-Part A in the Absence of Intercurrent Events (ICEs
* Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange) change from baseline to Week 24 in D-dimer levels.
Time frame: Week 24
Normalization of Markers of Hemolysis (LDH) at Week 24-Part A
Percentage of patients with LDH level within normal ranges and with an abnormal value at baseline.
Time frame: Week 24
Normalization of Markers of Hemolysis (Indirect Bilirubin) at Week 24-Part A
Percentage of patients with Indirect Bilirubin level within normal ranges and with an abnormal value at baseline.
Time frame: Week 24
Normalization of Markers of Hemolysis (ARC) at Week 24-Part A
Percentage of patients with ARC level within normal ranges and with an abnormal value at baseline.
Time frame: Week 24
Normalization of Markers of Hemolysis (Haptoglobin) at Week 24-Part A
Percentage of patients with haptoglobin level within normal ranges and with an abnormal value at baseline.
Time frame: Week 24
Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for Haptoglobin Levels-Part A
Percentage of patients with haptoglobin level normalization during the initial 24 weeks of the study
Time frame: Week 24
Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for Hemoglobin Levels-Part A
Percentage of patients with Hemoglobin level normalization during the initial 24 weeks of the study
Time frame: Week 24
Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for LDH Levels-Part A
Percentage of patients with LDH level normalization during the initial 24 weeks of the study
Time frame: Week 24
Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for Indirect Bilirubin Levels-Part A
Percentage of patients with Indirect Bilirubin level normalization during the initial 24 weeks of the study
Time frame: Week 24
Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for ARC Levels-Part A
Percentage of patients with ARC level normalization during the initial 24 weeks of the study
Time frame: Week 24
Number of Packed Red Blood Cell Units Transfused From Week 5 to Week 24-Part A
Number of PRBC units transfused from Week 5 and Week 24 was assessed
Time frame: Week 5 to Week 24
Change From Baseline to Week 24 in FACIT-F Subscale Score-Part A in the Absence of Intercurrent Events (ICEs)
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). The FACIT-F subscale is used to measure fatigue and its impact upon daily activities and function in patients with chronic illnesses and contains 20 items related to the impact of fatigue. Each item is scored on a 0-4 scale, with some items reverse-scored. Total scores range from 0 to 52, where higher scores indicate less fatigue and better outcomes, and lower scores reflect greater fatigue. It can be used alone or with other FACIT subscales as part of broader quality of life assessments.
Time frame: Week 24
Change From Baseline to Week 24 in SF-12-Part A in the Absence of Intercurrent Events (ICEs)
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange. SF-12 is a 12-item health survey assessing physical and mental health. Higher scores mean better health with scores above 50 indicating better than average health. It produces two summary scores: the Physical Component Summary (PCS) and Mental Component Summary (MCS), both norm-based (mean=50, SD=10), with ranges of \~5-80 (PCS) and \~-3.3-80 (MCS). Higher scores=better health. It also covers 8 subscales-Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE), and Mental Health (MH), each scored between 0-100, where higher=better functioning. Scores are computed using weighted formulas from item responses (not simple averages).
Time frame: Week 24
Change From Baseline to Week 24 in EQ-5D-5L Questionnaire -Part A in the Absence of Intercurrent Events (ICEs)
The EQ-5D-5L measures total health across 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression-each scored from 1 (no problems) to 5 (extreme problems). Scores form a 5-digit health profile (e.g., 12345). Each individual score plus a VAS for perceived health status today are separately reported. Higher scores reflect better total health. The EQ VAS is a patient-rated score from 0 (worst) to 100 (best health). The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange).
Time frame: Week 24
Change From Baseline to Week 48 in Hemoglobin (Hgb) Level-Part B in the Absence of Intercurrent Events (ICEs).
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from Baseline to Week 48 in Hemoglobin (Hgb) level.
Time frame: Week 48
Change From Baseline to Week 48 in LDH Level-Part B in the Absence of Intercurrent Events (ICEs).
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from Baseline to Week 48 in LDH level.
Time frame: Week 48
Change From Baseline to Week 48 in Haptoglobin Level-Part B in the Absence of Intercurrent Events (ICEs).
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from Baseline to Week 48 in Haptoglobin level
Time frame: Week 48
Change From Baseline to Week 48 in Indirect Bilirubin Level-Part B in the Absence of Intercurrent Events (ICEs).
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from Baseline to Week 48 in Indirect Bilirubin level.
Time frame: Week 48
Change From Baseline to Week 48 in ARC-Part B in the Absence of Intercurrent Events (ICEs)
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from baseline to Week 48 in Absolute reticulocyte counts (ARC).
Time frame: Week 48
Change From Baseline to Week 48 in D-dimer Levels-Part B in the Absence of Intercurrent Events (ICEs).
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from baseline to Week 48 in D-dimer levels.
Time frame: Week 48
Change From Baseline to Week 48 in FACT-An Scale Score (Quality of Life)-Part B in the Absence of Intercurrent Events (ICEs)
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug and plasma exchange. The FACT-An is used to measure quality of life (QoL) in patients with anemia. Each item is rated on a 5-point Likert scale:0=Not at all, 1=A little bit ,2=Somewhat, 3=Quite a bit, 4=Very much.Some items are reverse scored. Higher scores in this scale denote a better QoL with less impact of anemia. The total FACT-An scale score ranges from 0 to 160. The total score gives a comprehensive view of a patient's well-being. It combines the FACT-G with an Anemia subscale.FACT-G (27 items):Physical Well-Being (PWB) and Social/Family Well-Being (SWB) 14 items in total, Emotional Well-Being (EWB)-6 items, Functional Well-Being (FWB)-7 items, Anemia Subscale (AnS): 13 items. Total FACT-An score=FACT-G + Anemia Subscale=40 items
Time frame: Week 48
Change From Baseline to Week 48 in FACIT-F Subscale Score-Part B in the Absence of Intercurrent Events (ICEs).
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). The FACIT-F subscale is used to measure fatigue and its impact upon daily activities and function in patients with chronic illnesses and contains 20 items related to the impact of fatigue. Each item is scored on a 0-4 scale, with some items reverse-scored. Total scores range from 0 to 52, where higher scores indicate less fatigue and better outcomes, and lower scores reflect greater fatigue. It can be used alone or with other FACIT subscales as part of broader quality of life assessments.
Time frame: Week 48
Change From Baseline to Week 48 in EQ-5D-5L-Part B in the Absence of Intercurrent Events (ICEs).
The EQ-5D-5L measures total health across 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression-each scored from 1 (no problems) to 5 (extreme problems). Scores form a 5-digit health profile (e.g., 12345). Each individual score plus a VAS for perceived health status today are separately reported. Higher scores reflect better total health. The EQ VAS is a patient-rated score from 0 (worst) to 100 (best health). The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange).
Time frame: Week 48
Change From Baseline to Week 48 in SF-12-Part B in the Absence of Intercurrent Events (ICEs).
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange SF-12 is a 12-item health survey assessing physical and mental health. Higher scores mean better health with scores above 50 indicating better than average health. It produces two summary scores: the Physical Component Summary (PCS) and Mental Component Summary (MCS), both norm-based (mean = 50, SD =10), with ranges of \~5-80 (PCS) and \~-3.3-80 (MCS). Higher scores = better health. It also covers 8 subscales-Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE), and Mental Health (MH), each scored between 0-100, where higher=better functioning. Scores are computed using weighted formulas from item responses (not simple averages).
Time frame: Week 48
| Milestone | Pegcetacoplan Double Blind During Part A | Placebo Matching Pegcetacoplan-Double-blind During Part A |
|---|---|---|
| Started | 16 | 8 |
| Completed | 14 | 7 |
| Not completed | 2 | 1 |
| Milestone | Pegcetacoplan Double Blind During Part A | Placebo Matching Pegcetacoplan-Double-blind During Part A |
|---|---|---|
| Started | 14 | 7 |
| Completed | 8 | 3 |
| Not completed | 6 | 4 |
| Milestone | Pegcetacoplan Double Blind During Part A | Placebo Matching Pegcetacoplan-Double-blind During Part A |
|---|---|---|
| Started | 8 | 3 |
| Completed | 0 | 0 |
| Not completed | 8 | 3 |
A participant was considered to have a response if the Hgb level increased greater than or equal to (\>=) 1.5 gram per deciliter (g/dL) from baseline and this increase was maintained from Week 16 through Week 24 in absence of blood transfusion from Week 5 through Week 24.
| Participants | Pegcetacoplan Double Blind During Part A | Placebo Matching Pegcetacoplan-Double-blind During Part A |
|---|---|---|
| Number of Patients Achieving a Response (R) at Week 24 | 8 | 2 |
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange) Mean change from Baseline to Week 24 in Hemoglobin (Hgb) level.
| grams per deciliter (g/dL) | Pegcetacoplan Double Blind During Part A | Placebo Matching Pegcetacoplan-Double-blind During Part A |
|---|---|---|
| Change From Baseline to Week 24 in Hemoglobin (Hgb) Level-Part A in the Absence of Intercurrent Events (ICEs). | 2.85 ± 0.306 | 1.36 ± 0.278 |
Percentage of patients who did not receive a blood transfusion between Week 5 and Week 24 was assessed
| Participants | Pegcetacoplan Double Blind During Part A | Placebo Matching Pegcetacoplan-Double-blind During Part A |
|---|---|---|
| Number of Patients Achieving Transfusion Avoidance From Week 5 to Week 24-Part A | 12 (-0.374 to 0.691) | 5 (0 to 0) |
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). FACT-An is used to measure quality of life (QoL) in patients with anemia. Each item is rated on a 5-point Likert scale:0=Not at all, 1=A little bit ,2=Somewhat, 3=Quite a bit, 4=Very much. Some items are reverse scored. Higher scores in this scale denote a better QoL with less impact of anemia.The total FACT-An scale score ranges from 0 to 160. The total score gives a comprehensive view of a patient's well-being. It combines the FACT-G with an Anemia subscale. FACT-G (27 items):Physical Well-Being (PWB) and Social/Family Well-Being (SWB) 14 items in total, Emotional Well-Being (EWB)-6 items,Functional Well-Being (FWB)-7 items, Anemia Subscale (AnS): 13 items. Total FACT-An score=FACT-G + Anemia Subscale=40 item
| Units on a scale | Pegcetacoplan Double Blind During Part A | Placebo Matching Pegcetacoplan-Double-blind During Part A |
|---|---|---|
| Change From Baseline to Week 24 in FACT-An Scale Score (Quality of Life)-Part A in the Absence of Intercurrent Events (ICEs) | 20.67 ± 19.175 | 16.40 ± 37.246 |
Number of blood transfusions received between Week 5 and Week 24 were assessed.
| Number of transfusions | Pegcetacoplan Double Blind During Part A | Placebo Matching Pegcetacoplan-Double-blind During Part A |
|---|---|---|
| Number of Packed Red Blood Cell Transfusions Received by Patients From Week 5 to Week 24-Part A | 1.5 ± 3.62 | 1.1 ± 2.80 |
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange) Mean change from baseline to Week 24 in Lactate dehydrogenase (LDH) levels
| U/L | Pegcetacoplan Double Blind During Part A | Placebo Matching Pegcetacoplan-Double-blind During Part A |
|---|---|---|
| Change From Baseline to Week 24 in LDH Levels-Part A in the Absence of Intercurrent Events (ICEs) | -251.73 ± 211.312 | -82.00 ± 138.477 |
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from baseline to Week 24 in Haptoglobin level
| g/L | Pegcetacoplan Double Blind During Part A | Placebo Matching Pegcetacoplan-Double-blind During Part A |
|---|---|---|
| Change From Baseline to Week 24 in Haptoglobin Levels-Part A in the Absence of Intercurrent Events (ICEs) | 0.31 ± 0.493 | 0.01 ± 0.020 |
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from baseline to Week 24 in Indirect bilirubin level
| µmol/L | Pegcetacoplan Double Blind During Part A | Placebo Matching Pegcetacoplan-Double-blind During Part A |
|---|---|---|
| Change From Baseline to Week 24 in Indirect Bilirubin-Part A in the Absence of Intercurrent Events (ICE) | -31.55 ± 23.340 | 8.20 ± 19.325 |
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from baseline to Week 24 in Absolute reticulocyte counts (ARC).
| 10^9 cells/L | Pegcetacoplan Double Blind During Part A | Placebo Matching Pegcetacoplan-Double-blind During Part A |
|---|---|---|
| Change From Baseline to Week 24 in ARC-Part A in the Absence of Intercurrent Events (ICEs) | -41.17 ± 62.438 | -37.96 ± 19.891 |
* Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange) change from baseline to Week 24 in D-dimer levels.
| µg/L FEU | Pegcetacoplan Double Blind During Part A | Placebo Matching Pegcetacoplan-Double-blind During Part A |
|---|---|---|
| Change From Baseline to Week 24 in D-dimer Levels-Part A in the Absence of Intercurrent Events (ICEs | -698.70 ± 927.480 | -1722.75 ± 3089.162 |
Percentage of patients with LDH level within normal ranges and with an abnormal value at baseline.
| Participants | Pegcetacoplan Double Blind During Part A | Placebo Matching Pegcetacoplan-Double-blind During Part A |
|---|---|---|
| Normalization of Markers of Hemolysis (LDH) at Week 24-Part A | 5 | 1 |
Percentage of patients with Indirect Bilirubin level within normal ranges and with an abnormal value at baseline.
| Participants | Pegcetacoplan Double Blind During Part A | Placebo Matching Pegcetacoplan-Double-blind During Part A |
|---|---|---|
| Normalization of Markers of Hemolysis (Indirect Bilirubin) at Week 24-Part A | 9 | 1 |
Percentage of patients with ARC level within normal ranges and with an abnormal value at baseline.
| Participants | Pegcetacoplan Double Blind During Part A | Placebo Matching Pegcetacoplan-Double-blind During Part A |
|---|---|---|
| Normalization of Markers of Hemolysis (ARC) at Week 24-Part A | 4 | 2 |
Percentage of patients with haptoglobin level within normal ranges and with an abnormal value at baseline.
| Participants | Pegcetacoplan Double Blind During Part A | Placebo Matching Pegcetacoplan-Double-blind During Part A |
|---|---|---|
| Normalization of Markers of Hemolysis (Haptoglobin) at Week 24-Part A | 4 | 0 |
Percentage of patients with haptoglobin level normalization during the initial 24 weeks of the study
| Participants | Pegcetacoplan Double Blind During Part A | Placebo Matching Pegcetacoplan-Double-blind During Part A |
|---|---|---|
| Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for Haptoglobin Levels-Part A | 7 | 0 |
Percentage of patients with Hemoglobin level normalization during the initial 24 weeks of the study
| Participants | Pegcetacoplan Double Blind During Part A | Placebo Matching Pegcetacoplan-Double-blind During Part A |
|---|---|---|
| Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for Hemoglobin Levels-Part A | 7 | 0 |
Percentage of patients with LDH level normalization during the initial 24 weeks of the study
| Participants | Pegcetacoplan Double Blind During Part A | Placebo Matching Pegcetacoplan-Double-blind During Part A |
|---|---|---|
| Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for LDH Levels-Part A | 6 | 2 |
Percentage of patients with Indirect Bilirubin level normalization during the initial 24 weeks of the study
| Participants | Pegcetacoplan Double Blind During Part A | Placebo Matching Pegcetacoplan-Double-blind During Part A |
|---|---|---|
| Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for Indirect Bilirubin Levels-Part A | 11 | 1 |
Percentage of patients with ARC level normalization during the initial 24 weeks of the study
| Participants | Pegcetacoplan Double Blind During Part A | Placebo Matching Pegcetacoplan-Double-blind During Part A |
|---|---|---|
| Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for ARC Levels-Part A | 9 | 3 |
Number of PRBC units transfused from Week 5 and Week 24 was assessed
| Number of PRBC units transfused | Pegcetacoplan Double Blind During Part A | Placebo Matching Pegcetacoplan-Double-blind During Part A |
|---|---|---|
| Number of Packed Red Blood Cell Units Transfused From Week 5 to Week 24-Part A | 2.47 ± 5.944 | 1.88 ± 4.549 |
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). The FACIT-F subscale is used to measure fatigue and its impact upon daily activities and function in patients with chronic illnesses and contains 20 items related to the impact of fatigue. Each item is scored on a 0-4 scale, with some items reverse-scored. Total scores range from 0 to 52, where higher scores indicate less fatigue and better outcomes, and lower scores reflect greater fatigue. It can be used alone or with other FACIT subscales as part of broader quality of life assessments.
| Units on a scale | Pegcetacoplan Double Blind During Part A | Placebo Matching Pegcetacoplan-Double-blind During Part A |
|---|---|---|
| Change From Baseline to Week 24 in FACIT-F Subscale Score-Part A in the Absence of Intercurrent Events (ICEs) | 9.73 ± 11.028 | 8.80 ± 18.130 |
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange. SF-12 is a 12-item health survey assessing physical and mental health. Higher scores mean better health with scores above 50 indicating better than average health. It produces two summary scores: the Physical Component Summary (PCS) and Mental Component Summary (MCS), both norm-based (mean=50, SD=10), with ranges of \~5-80 (PCS) and \~-3.3-80 (MCS). Higher scores=better health. It also covers 8 subscales-Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE), and Mental Health (MH), each scored between 0-100, where higher=better functioning. Scores are computed using weighted formulas from item responses (not simple averages).
| units on a scale | Pegcetacoplan Double Blind During Part A | Placebo Matching Pegcetacoplan-Double-blind During Part A |
|---|---|---|
| Physical Component Score at Week 24 | 4.95 ± 7.965 | 4.46 ± 11.867 |
| Mental Component Score at Week 24 | 5.53 ± 9.935 | 2.50 ± 9.777 |
The EQ-5D-5L measures total health across 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression-each scored from 1 (no problems) to 5 (extreme problems). Scores form a 5-digit health profile (e.g., 12345). Each individual score plus a VAS for perceived health status today are separately reported. Higher scores reflect better total health. The EQ VAS is a patient-rated score from 0 (worst) to 100 (best health). The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange).
| units on a scale | Pegcetacoplan Double Blind During Part A | Placebo Matching Pegcetacoplan-Double-blind During Part A |
|---|---|---|
| Mobility-Part A | 0.50 ± 1.087 | 0.00 ± 1.633 |
| Self-care-Part A | 0.00 ± 0.447 | 1.00 ± 1.414 |
| Usual activities-Part A | 0.58 ± 0.669 | 0.00 ± 0.816 |
| Pain/Discomfort-Part A | 0.25 ± 0.866 | -0.75 ± 1.258 |
| Anxiety/Depression-Part A | 0.33 ± 0.492 | 0.00 ± 0.816 |
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from Baseline to Week 48 in Hemoglobin (Hgb) level.
| grams per deciliter (g/dL) | Open-label Pegcetacoplan During Part B | Open-label Pegcetacoplan (Placebo Matching Pegcetacoplan During Part A) During Part B |
|---|---|---|
| Change From Baseline to Week 48 in Hemoglobin (Hgb) Level-Part B in the Absence of Intercurrent Events (ICEs). | 3.00 ± 2.101 | 3.35 ± 0.995 |
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from Baseline to Week 48 in LDH level.
| U/L | Open-label Pegcetacoplan During Part B | Open-label Pegcetacoplan (Placebo Matching Pegcetacoplan During Part A) During Part B |
|---|---|---|
| Change From Baseline to Week 48 in LDH Level-Part B in the Absence of Intercurrent Events (ICEs). | -220.25 ± 168.347 | -259.25 ± 52.258 |
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from Baseline to Week 48 in Haptoglobin level
| grams per deciliter (g/dL) | Open-label Pegcetacoplan During Part B | Open-label Pegcetacoplan (Placebo Matching Pegcetacoplan During Part A) During Part B |
|---|---|---|
| Change From Baseline to Week 48 in Haptoglobin Level-Part B in the Absence of Intercurrent Events (ICEs). | 0.18 ± 0.238 | 0.69 ± 0.262 |
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from Baseline to Week 48 in Indirect Bilirubin level.
| µmol/L | Open-label Pegcetacoplan During Part B | Open-label Pegcetacoplan (Placebo Matching Pegcetacoplan During Part A) During Part B |
|---|---|---|
| Change From Baseline to Week 48 in Indirect Bilirubin Level-Part B in the Absence of Intercurrent Events (ICEs). | -40.19 ± 28.546 | -33.43 ± 25.237 |
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from baseline to Week 48 in Absolute reticulocyte counts (ARC).
| 10^9 cells/L | Open-label Pegcetacoplan During Part B | Open-label Pegcetacoplan (Placebo Matching Pegcetacoplan During Part A) During Part B |
|---|---|---|
| Change From Baseline to Week 48 in ARC-Part B in the Absence of Intercurrent Events (ICEs) | -39.64 ± 55.966 | -118.20 ± 73.076 |
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from baseline to Week 48 in D-dimer levels.
| µg/L FEU | Open-label Pegcetacoplan During Part B | Open-label Pegcetacoplan (Placebo Matching Pegcetacoplan During Part A) During Part B |
|---|---|---|
| Change From Baseline to Week 48 in D-dimer Levels-Part B in the Absence of Intercurrent Events (ICEs). | -596.63 ± 937.910 | -3595.00 ± 4879.037 |
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug and plasma exchange. The FACT-An is used to measure quality of life (QoL) in patients with anemia. Each item is rated on a 5-point Likert scale:0=Not at all, 1=A little bit ,2=Somewhat, 3=Quite a bit, 4=Very much.Some items are reverse scored. Higher scores in this scale denote a better QoL with less impact of anemia. The total FACT-An scale score ranges from 0 to 160. The total score gives a comprehensive view of a patient's well-being. It combines the FACT-G with an Anemia subscale.FACT-G (27 items):Physical Well-Being (PWB) and Social/Family Well-Being (SWB) 14 items in total, Emotional Well-Being (EWB)-6 items, Functional Well-Being (FWB)-7 items, Anemia Subscale (AnS): 13 items. Total FACT-An score=FACT-G + Anemia Subscale=40 items
| Units on a scale | Open-label Pegcetacoplan During Part B | Open-label Pegcetacoplan (Placebo Matching Pegcetacoplan During Part A) During Part B |
|---|---|---|
| Change From Baseline to Week 48 in FACT-An Scale Score (Quality of Life)-Part B in the Absence of Intercurrent Events (ICEs) | 29.20 ± 19.113 | 39.50 ± 29.771 |
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). The FACIT-F subscale is used to measure fatigue and its impact upon daily activities and function in patients with chronic illnesses and contains 20 items related to the impact of fatigue. Each item is scored on a 0-4 scale, with some items reverse-scored. Total scores range from 0 to 52, where higher scores indicate less fatigue and better outcomes, and lower scores reflect greater fatigue. It can be used alone or with other FACIT subscales as part of broader quality of life assessments.
| Units on a scale | Open-label Pegcetacoplan During Part B | Open-label Pegcetacoplan (Placebo Matching Pegcetacoplan During Part A) During Part B |
|---|---|---|
| Change From Baseline to Week 48 in FACIT-F Subscale Score-Part B in the Absence of Intercurrent Events (ICEs). | 11.82 ± 11.252 | 21.75 ± 14.315 |
The EQ-5D-5L measures total health across 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression-each scored from 1 (no problems) to 5 (extreme problems). Scores form a 5-digit health profile (e.g., 12345). Each individual score plus a VAS for perceived health status today are separately reported. Higher scores reflect better total health. The EQ VAS is a patient-rated score from 0 (worst) to 100 (best health). The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange).
| Units on a scale | Open-label Pegcetacoplan During Part B | Open-label Pegcetacoplan (Placebo Matching Pegcetacoplan During Part A) During Part B |
|---|---|---|
| Mobility-Part B | 0.60 ± 1.174 | 1.25 ± 1.708 |
| Self-care-Part B | 0.10 ± 0.316 | 1.25 ± 0.957 |
| Usual activities-Part B | 0.70 ± 0.949 | 0.75 ± 1.258 |
| Pain/Discomfort-Part B | 0.40 ± 0.966 | 1.00 ± 1.414 |
| Anxiety/Depression-Part B | 0.30 ± 0.483 | 0.00 ± 1.414 |
The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange SF-12 is a 12-item health survey assessing physical and mental health. Higher scores mean better health with scores above 50 indicating better than average health. It produces two summary scores: the Physical Component Summary (PCS) and Mental Component Summary (MCS), both norm-based (mean = 50, SD =10), with ranges of \~5-80 (PCS) and \~-3.3-80 (MCS). Higher scores = better health. It also covers 8 subscales-Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE), and Mental Health (MH), each scored between 0-100, where higher=better functioning. Scores are computed using weighted formulas from item responses (not simple averages).
| units on a scale | Open-label Pegcetacoplan During Part B | Open-label Pegcetacoplan (Placebo Matching Pegcetacoplan During Part A) During Part B |
|---|---|---|
| Physical Component Score at Week 48 | 7.70 ± 8.318 | 14.49 ± 9.197 |
| Mental Component Score at Week 48 | 3.93 ± 12.465 | 4.10 ± 8.606 |
Collected over Through study completion and follow-up for up to 104 weeks (24 months approximately).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pegcetacoplan Double Blind During Part A | 1/16 (6.3%) | 5/16 (31.3%) | 16/16 (100%) |
| Placebo Matching Pegcetacoplan-Double-blind During Part A | 0/8 (0%) | 1/8 (12.5%) | 8/8 (100%) |
| Open-label Pegcetacoplan During Parts B and C | 0/14 (0%) | 6/14 (42.9%) | 12/14 (85.7%) |
| Open-label Pegcetacoplan (Placebo Matching Pegcetacoplan during Part A) During Parts B&C | 0/7 (0%) | 1/7 (14.3%) | 4/7 (57.1%) |
| Event | Pegcetacoplan Double Blind During Part A | Placebo Matching Pegcetacoplan-Double-blind During Part A | Open-label Pegcetacoplan During Parts B and C | Open-label Pegcetacoplan (Placebo Matching Pegcetacoplan during Part A) During Parts B&C |
|---|---|---|---|---|
| Autoimmune haemolytic anaemiaBlood and lymphatic system disorders | 0/16 | 0/8 | 1/14 | 1/7 |
| Cold type haemolytic anaemiaBlood and lymphatic system disorders | 0/16 | 0/8 | 2/14 | 0/7 |
| Covid-19Infections and infestations | 0/16 | 1/8 | 0/14 | 0/7 |
| Acute kidney injuryRenal and urinary disorders | 0/16 | 0/8 | 1/14 | 0/7 |
| Atrial fibrillationCardiac disorders | 0/16 | 0/8 | 1/14 | 0/7 |
| Breakthrough haemolysisBlood and lymphatic system disorders | 0/16 | 0/8 | 1/14 | 0/7 |
| Cardiac failureCardiac disorders | 0/16 | 0/8 | 1/14 | 0/7 |
| HaemolysisBlood and lymphatic system disorders | 0/16 | 0/8 | 1/14 | 0/7 |
| Osteonecrosis of jawMusculoskeletal and connective tissue disorders | 0/16 | 0/8 | 1/14 | 0/7 |
| Covid-19 pneumoniaInfections and infestations | 1/16 | 0/8 | 0/14 | 0/7 |
| Event | Pegcetacoplan Double Blind During Part A | Placebo Matching Pegcetacoplan-Double-blind During Part A | Open-label Pegcetacoplan During Parts B and C | Open-label Pegcetacoplan (Placebo Matching Pegcetacoplan during Part A) During Parts B&C |
|---|---|---|---|---|
| Oedema peripheralGeneral disorders | 3/16 | 3/8 | 0/14 | 0/7 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/16 | 2/8 | 0/14 | 0/7 |
| Covid-19Infections and infestations | 3/16 | 1/8 | 3/14 | 0/7 |
| Cold type haemolytic anaemiaBlood and lymphatic system disorders | 2/16 | 0/8 | 3/14 | 0/7 |
| FatigueGeneral disorders | 3/16 | 0/8 | 0/14 | 0/7 |
| Upper respiratory tract infectionInfections and infestations | 3/16 | 0/8 | 1/14 | 0/7 |
| Gait disturbanceGeneral disorders | 0/16 | 0/8 | 0/14 | 1/7 |
| PneumoniaInfections and infestations | 1/16 | 0/8 | 2/14 | 0/7 |
| CystitisInfections and infestations | 0/16 | 0/8 | 0/14 | 1/7 |
| InfluenzaInfections and infestations | 0/16 | 1/8 | 0/14 | 1/7 |
All demographic characteristics are characterized by treatment group for Parts A (placebo and pegcetacoplan along with the totals) and B (total). Part A was double blinded and Part B was open-label.
| Age, Categorical(Participants) | Pegcetacoplan Double Blind During Part A | Placebo Matching Pegcetacoplan-Double-blind During Part A | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 1 | 4 |
| >=65 years | 13 | 7 | 20 |
| Sex: Female, Male(Participants) | Pegcetacoplan Double Blind During Part A | Placebo Matching Pegcetacoplan-Double-blind During Part A | Total |
|---|---|---|---|
| Female | 6 | 6 | 12 |
| Male | 10 | 2 | 12 |
| Race (NIH/OMB)(Participants) | Pegcetacoplan Double Blind During Part A | Placebo Matching Pegcetacoplan-Double-blind During Part A | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 4 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 12 | 8 | 20 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Disease History-Time since diagnosis(Years) | Pegcetacoplan Double Blind During Part A | Placebo Matching Pegcetacoplan-Double-blind During Part A | Total |
|---|---|---|---|
| Mean | 6.0 ± 5.09 | 7.0 ± 8.60 | 6.3 ± 6.30 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2022 to primary completion in May 2024, 19 months.
Results were first posted in Oct 2025, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegcetacoplan
Anemia, Hemolytic, Autoimmune →